首页> 外文期刊>海南医科大学学报(英文版) >Effect of interleukin-2+pirarubicin infusion chemotherapy combined with systemic chemotherapy on the malignant biological behavior of advanced bladder cancer
【24h】

Effect of interleukin-2+pirarubicin infusion chemotherapy combined with systemic chemotherapy on the malignant biological behavior of advanced bladder cancer

机译:白细胞介素2+吡柔比星输注化疗联合全身化疗对晚期膀胱癌恶性生物学行为的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To study the effect of interleukin-2 + pirarubicin infusion chemotherapy combined with systemic chemotherapy on the malignant biological behavior of advanced bladder cancer. Methods: Patients with advanced bladder cancer who were treated in Tongcheng People''s Hospital between April 2015 and July 2016 were selected as the research subjects and randomly divided into group A who received interleukin-2 + pirarubicin infusion chemotherapy combined with systemic chemotherapy and the group B who received pirarubicin infusion chemotherapy combined with systemic chemotherapy. The contents of tumor markers and cytokines and the expression of apoptosis molecules in the urine were detected before and after chemotherapy. Results: 8 weeks after chemotherapy, BLCA-1, BLCA-4, CYFRA21-1, TGF-β1, VEGF, EGF, HGF and IGF-2 contents in urine of both groups of patients were significantly lower than those before treatment, Fas, Bad, PTEN and Beclin-1 mRNA expression in urine were significantly higher than those before treatment and BLCA-1, BLCA-4, CYFRA21-1, TGF-β1, VEGF, EGF, HGF and IGF-2 contents in urine of group A were significantly lower than those of group B, Fas, Bad, PTEN and Beclin-1 mRNA expression in urine were significantly higher than those of group B. Conclusion: Interleukin-2+ pirarubicin infusion chemotherapy combined with systemic chemotherapy can be more effective than pirarubicin infusion chemotherapy combined with systemic chemotherapy in inhibiting the malignant biological behavior of advanced bladder cancer.
机译:目的:研究白介素2 +吡柔比星输注化疗联合全身化疗对晚期膀胱癌恶性生物学行为的影响。方法:选择2015年4月至2016年7月在桐城市市人民医院接受治疗的晚期膀胱癌患者作为研究对象,随机分为A组,分别接受白细胞介素2 +吡柔比星输注化疗联合全身化疗和化疗。 B组接受吡柔比星输注化疗和全身化疗。检测化疗前后尿液中肿瘤标志物和细胞因子的含量以及细胞凋亡分子的表达。结果:化疗后8周,两组患者尿液中BLCA-1,BLCA-4,CYFRA21-1,TGF-β1,VEGF,EGF,HGF和IGF-2的含量均明显低于治疗前,Fas,尿中Bad,PTEN和Beclin-1 mRNA的表达均显着高于治疗前,A组尿中BLCA-1,BLCA-4,CYFRA21-1,TGF-β1,VEGF,EGF,HGF和IGF-2的含量明显低于B组,尿中Fas,Bad,PTEN和Beclin-1 mRNA表达均显着高于B组。结论:白细胞介素2+吡柔比星输注化疗联合全身化疗比吡柔比星更有效输注化疗与全身化疗联合抑制晚期膀胱癌的恶性生物学行为。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号